Follow the Pundits
Tag: hub-insiders
🎩 Pershing Square USA (PSUS): IPO Drop, Insider Skill & the Ackman Question
Bill Ackman’s Pershing Square USA (PSUS) IPO promised Berkshire-style investing for the digital age—but the market responded with an 18% drop on day one. Is this a rare opportunity to buy elite hedge fund skill at a discount, or a structural trap hiding behind influence?
Sweetgreen (SG): 90% Down—Turnaround or Trap? 🥗📉
Sweetgreen looks fresh on the menu—but the stock tells a different story. With high short interest, insider buying, and weak fundamentals, SG is a high-risk contrarian bet investors should approach carefully.
Revisiting The Case of CRISPR Therapeutics: Still Crisp, Still Risky, Still Dangerously Alluring
CRISPR Therapeutics (CRSP) has the first widely approved CRISPR-based therapy, huge insider buying near today’s price, and institutions (including ARK) deep in the name — while shorts pile on. Crisp setup, risky execution, dangerously alluring upside. 🧬🎯
Fundamental Research–Driven Fund Voss Capital Buys PAR Technology: Time to Shop?
PAR Technology is shifting from legacy hardware to a unified restaurant SaaS platform. After Voss Capital’s $7.1M buy, massive institutional ownership, and heavy short interest, the setup looks like an inflection-point story—high upside if execution clicks, sharp downside if it doesn’t.
Insiders Are Buying Under Armour: Strong Suit or Skip the Knight-Mare?
Under Armour trades over 90% below its all-time high—but insiders are buying aggressively. Is this a rare turnaround opportunity or a classic value trap? Let’s break it down.
Baker Bros Are Bullish — Can Kodiak Kill the Bears?
When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.
Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?
A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.
Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?
Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?
Could MGM Suddenly Stand for “My Great Money-Maker?”
Barry Diller is doubling down, insiders are buying, and MGM’s digital arm is gaining traction. Is the casino giant quietly becoming a global money machine again?
New CEO and Activist Corvex’s Keith Meister Buy Vestis; Expect Profits or Casual Tees?
A new CEO with UPS DNA, millions in insider buys, and activist hedge fund Corvex circling… Vestis stock checks many contrarian boxes. But high leverage and a slow turnaround mean this is not for the faint of heart. 👕📈